Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results

Halozyme Therapeutics (NASDAQ:HALO) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49, FiscalAI reports. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.54 earnings per share. Halozyme Therapeutics updated its FY 2026 guidance to 8.650-9.000 EPS.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Record second-quarter performance: Total revenue rose 48% year over year to $481 million, while royalty revenue increased 50% to $307.7 million. Adjusted EBITDA reached $328.8 million and non-GAAP EPS was $2.28.
• 2026 guidance was raised: Halozyme now expects total revenue of $1.835 billion-$1.91 billion, royalty revenue of $1.22 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.28 billion, and non-GAAP EPS of $8.65-$9.00.
• ENHANZE product diversification accelerated: Royalties from newer launches—including OCREVUS ZUNOVO, Opdivo Qvantig, and RYBREVANT SC—increased approximately 80% sequentially, complementing continued growth from DARZALEX SC, VYVGART Hytrulo, and PHESGO.
• Strong partnership momentum expanded the long-term pipeline: Halozyme signed five collaboration and licensing agreements across the quarter and July, including deals with GSK, Incyte, Vertex, and Oruka, generating $35.5 million in upfront revenue and expanding ENHANZE into ADCs and nucleic-acid therapies.
• Litigation remains an important uncertainty: Halozyme is pursuing injunctions against Merck in roughly eight countries and plans to appeal four U.S. patent-review decisions, although management expressed strong confidence it will ultimately prevail.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $17.36 during mid-day trading on Friday, hitting $103.12. The company had a trading volume of 7,633,759 shares, compared to its average volume of 1,834,638. The company has a market capitalization of $12.23 billion, a price-to-earnings ratio of 37.09, a P/E/G ratio of 0.35 and a beta of 0.85. Halozyme Therapeutics has a 12-month low of $61.22 and a 12-month high of $103.30. The company’s fifty day moving average is $75.74 and its 200-day moving average is $71.25. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the sale, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,477 shares of company stock valued at $5,102,643 in the last three months. 2.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership increased its stake in shares of Halozyme Therapeutics by 29.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares in the last quarter. Federated Hermes Inc. grew its holdings in Halozyme Therapeutics by 8.5% in the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after purchasing an additional 123,917 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,379,575 shares of the biopharmaceutical company’s stock valued at $92,845,000 after purchasing an additional 8,391 shares during the period. Finally, Caisse de depot et placement du Quebec increased its position in shares of Halozyme Therapeutics by 57.6% in the fourth quarter. Caisse de depot et placement du Quebec now owns 1,224,009 shares of the biopharmaceutical company’s stock valued at $82,376,000 after buying an additional 447,374 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 earnings beat: Halozyme reported adjusted earnings of $2.28 per share, versus the $1.79-$1.82 consensus range, while revenue rose 48% year over year to $481 million, well above the roughly $402 million estimate. Royalty revenue increased 50% to $308 million, highlighting continued momentum in the company’s ENHANZE platform. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised 2026 guidance: The company now expects revenue of $1.835-$1.910 billion, royalty revenue of $1.220-$1.245 billion, adjusted EBITDA of $1.225-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the prior consensus estimate of $8.02, signaling management’s confidence in sustained growth. Halozyme Q2 Earnings Beat Estimates
• Positive Sentiment: Business development exceeded expectations: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, already surpassing its full-year goal of three. These agreements could expand future royalty and licensing revenue.
• Positive Sentiment: Analyst support improved: Leerink Partners upgraded HALO to “outperform” with a $110 target, while HC Wainwright raised its target to $115 and maintained a “buy” rating.
• Neutral Sentiment: Citizens JMP raised its target to $93 and kept a “market outperform” rating; Wells Fargo lifted its target to $95 but maintained an “equal weight” rating. Both targets remain below the current trading level, indicating some analyst caution after the rally.
• Negative Sentiment: With HALO trading near its 52-week high, valuation and profit-taking risks may limit additional near-term gains despite the strong fundamental update.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of research reports. TD Cowen lifted their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 31st. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday. Finally, UBS Group restated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.